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1. Introduction 
Since many decades, medical doctors and researchers have been intrigued by the possible 
beneficial contribution of the immune system in the long-lasting combat against cancer. 
Both in the cellular and humoral immunity arms, powerful tools are available to target the 
cancer cell. Moreover, the gradual shift of a focus on aspecific reinforcement of the innate 
immune system towards a specifically activated adaptive immunity in order to reject 
cancer cells has dominated the field of the last 10 to 20 years(1). Restorative 
immunotherapy in which cytokine balances are restored or reset and aspecific adoptive 
immunotherapy using e.g. natural killer (NK) cells or lymphokine-activated killer (LAK) 
cells are classical representations of the first wave. Specific adoptive immunotherapy 
using ex vivo activated antitumor cytotoxic T cells and especially active specific 
immunotherapy (‘cancer vaccines’) are representative for the second wave. Thorough 
changes in the underlying basic immunology mechanism guide these novel approaches. 
To date, only the different variants of cancer vaccines are able to induce an immunological 
memory, as such being the only approach potentially protecting the patients for future 
cancer re-challenges(2). A perceived low rate of classical objective responses, restricted to 
volume changes of a measurable tumor burden, has been the principal body of criticism 
against these therapies.  
Several new insights however, especially focusing on changes in the micro-environment 
of the tumors, are only starting to be unraveled. Without any doubt, they’re already now 
revealing much more than the previous tips of the curtains. Nowadays, converging 
evidence is being gained in a rapid way, for the need to move towards a third wave of 
immunotherapy approaches, those of the multimodal integrated immunotherapy 
paradigms, considering all the relevant players in the complex field of tumor 
immunology. 
2. Proof of the principle: A solid body of preclinical evidence 
The idea to actively prime cytotoxic T cells to specifically kill a tumor target cell has become 
a well established scientific fact. Several approaches all aiming to induce specifically 
activated, tumor-rejecting effector T cells have been investigated and found to be 
reproducible and reliable technologies. Genetically engineered tumor cells but especially 
autologous dendritic cells charged with tumor associated antigens have become the most 
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potent and popular immunological adjuvants to install an active anti-tumoral 
immunity(3;4). An additional advantage of the latter is the activation of both the innate and 
adaptive immunity arms of the patient. The mechanisms underlying this antitumoral 
priming capacity of dendritic cells seem to be fully consistent with the established 
paradigms of antigen uptake, processing and presentation. The exclusive potential of DC to 
present and cross-present exogenous antigens in the same antigen presenting cell is the 
critical characteristic for a successful antigen presentation to cytotoxic and helper T cells. DC 
pick up tumor-associated  antigens from diverse sources, process them and present them in 
both an Major Histocompatibility Complex (MHC) class I and II context to cytotoxic and 
helper T cells respectively. This has been clearly shown, also for glioma associated antigens 
from a whole-tumor-cell lysate(5). To date, efficient priming of the patient by dendritic cells 
implies four sequences of interaction between the dendritic cell and the T cell. Upon binding 
of the T cell receptor with the MHC complex on the antigen presenting cell displaying the 
appropriate epitope, a specific activation of the antitumor T cells with high enough avidity 
for the epitope takes place. Expansion of this T cell clones requires co-stimulatory molecules 
on the DC. A polarized immune response, preferentially with a Th-1 cytokine profile, 
should result from the previous interactions. Finally, some indication about the target 
location should be transferred to the T cells leading to the appropriate T cell homing 
properties(6-8). 
Many rodent models have demonstrated that prophylactic vaccination of mice with 
tumor-antigen loaded DC can protect immune competent animals from tumor challenge 
and outgrow. The most relevant experiments are being performed with syngeneic mice-
tumor models, to prove the efficacy of the vaccination in an autologous setting 
underscoring the possibility to break tolerance for self-derived antigens. Moreover, one 
can raise an anti-tumor immunological memory to make mice survive a re-challenge of 
cancer cells. More elaborated manipulations of the immune system like e.g. regulatory T 
cell depletion before vaccination even yield a much stronger protective effect in up to 
100% of the exposed animals(9;10). The step towards therapeutic vaccination models, 
being more relevant for the clinical reality of all day can be made if the crucial timing of 
inoculation and vaccination is being respected. Probably also due to the aggressive nature 
of the investigated models, where all mice are dead within  3 weeks after tumor 
inoculation, it appears crucial to vaccinate the animals not later than one week after the 
tumor inoculations. After that period, the course of the disease can hardly be influenced, 
presumably because of the establishment of an efficient immune suppressive, pro-tumor 
micro-environment around the tumor inocula. This should be understood as the  first 
evidence to use DC vaccinations as an adjuvant therapy in minimal residual disease 
settings, resembling most the prophylactic setting in which anti-tumor vaccines are so 
efficient. 
3. From proof of the principle to proof of efficacy 
Tumor vaccination therapy, even in its more basic form did yield some interesting results 
in terms of benefit in overall survival in several fields of oncology e.g. renal cell 
carcinoma, prostate carcinoma, non-small cell lung cancer, colon carcinoma and 
others(11). Historically, most attention has been paid to so called immunogenic tumors 
like melanomas. Although proof of the principle has been extensively demonstrated in 
these tumors using different vaccine approaches and the clinical results obtained until 
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now are equivalent to standard of care chemotherapy regimens, the final results of 
immunotherapy in these entities are still modest. Malignant gliomas, the most common 
primary brain tumors have always been considered to be not suitable for immunotherapy 
because of their location in the immune privileged central nervous system. To date 
however, we know that all the obstacles like the blood brain barrier, the lack of lymphatic 
vessels, the lack of residing antigen presenting cells in the brain, the low MHC expression 
on the tumor target cells are quite relative. They don’t seem to hamper the documented 
immune responses in patients harboring such tumors(12). To the current understanding 
the real hurdles in glioma vaccination strategies are the multiple immunosuppressive 
pathways orchestrated by this type of cancer cells and the lack of  universally expressed 
glioma associated antigens that are really crucial for tumor cell survival. Surprisingly, 
preliminary data might be pointing to an exploitable  lack of spontaneous 
immunogenicity of malignant gliomas. As such, they develop in a micro-environment 
protecting them from too extensive immune editing: especially that characteristic could be 
of major help to try to reset the patients’ immunity resulting in a much better immune 
rejection or control since the original immune-sensitive  tumor clones have not yet been 
eliminated by the natural immune surveillance mechanisms(13). 
Immune responses in the brain always elicit some fear for potentially disastrous 
consequences of an auto-immune attack by the patient’s immunity. Unlike vitiligo or even 
destruction of normal prostate tissue, an auto-immune encephalomyelitis could result in 
devastating neurological symptoms and deficits. Until now however, no preclinical –other 
than in a heavily manipulated immune environment- and no clinical data have been 
published showing any suspicion of serious auto-immunity in the central nervous system, 
using  tumor vaccination strategies. Moreover, numerous phase I and small phase II trials 
have been published showing the safety and the very attractive low toxicity profile of 
dendritic cell vaccines in brain cancer. As we’re still dealing with a palliative  treatment 
thus far, this perfect patient tolerance profile is highly valuable to build  upon for 
upcoming vaccination strategies. Although today’s technology to produce autologous 
dendritic cell vaccines is still very labour-intensive, it proved to be perfectly feasible to 
implement it in the daily clinical practice, both in the case of relapsed or newly diagnosed 
high grade gliomas.  
The main criticism against tumor vaccine approaches, often raised till today, comprises 
the presumed low rate of objective tumor responses. Objective, radiological responses as 
defined according to RECIST(14) or McDonalds(15) criteria have indeed been developed 
for radio-and especially chemotherapy regimens during which one aims to reduce the 
measurable tumor load in the patient. Although they provide valuable information in 
terms of proof of the principle of the investigated chemotherapy, they should not be 
considered a synonym for clinically relevant efficacy: in only a few cases, one was really 
able to demonstrate a clear correlation between objective responses and overall survival 
benefits(16). More intriguing even is the existence of the so-called ‘pseudo-progression’ 
since radiochemotherapy with temozolomid became the standard of care(17). In up to 25% 
(or even 40%) of cases, one might see an initial increase in radiological tumor volume, 
rather early after the concomitant radiochemotherapy: strikingly, often especially these 
patients seem to have a better overall survival chance than the group not displaying these 
types of misleading radiological changes. Dendritic cell vaccination is known to cause 
similar radiological images in which transient contrast-enhancements on magnetic 
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resonance imaging (MRI) might represent inflammatory, vaccine-induced radiological 
changes that can easily be mistaken for disease progression(18). Although the available  
literature mentions objective responses in about 13% of vaccinated patients with high 
grade gliomas, objective responses are not the most appropriate outcome measure for this 
therapy nor for other experimental therapies. Especially the growing consensus that 
immunotherapy should be used as an adjuvant treatment for minimal residual disease 
settings, implies that in many cases there will be no measurable tumor volume at the start 
of the treatment. Indeed, not all patients today are good candidates to possibly benefit 
from DC-based immunotherapy. Only tumors amenable to meaningful surgical resections 
should be considered candidates for adjuvant DC vaccination(19). Several reasons exist 
for that restriction: first of all one need enough tumor specimen to obtain tumor 
associated antigens. Secondly, one should be able to stably wean the patient from peri-
operative steroids, which might dampen an efficient immune response in case of 
vaccinations under steroids. Thirdly, by reducing the bulky tumor load, one partially 
corrects the immune suppressive environment, both locally and systemically, that results 
from the presence of an organized tumor. In that context, one should mention that 
modern resection techniques like the use of 5-ALA induced fluorescence guided 
resections, leading to more extensive glioma resections, can be a complement to the 
postoperative DC vaccination. 
In the past, many researchers have focused on the measurable immune responses in the 
blood of vaccinated patients as a surrogate endpoint and even as a surrogate of the desired 
objective clinical responses. The many immunological assays like delayed type 
hypersensitivity (DTH) reactions – even with skin biopsies of the test sites - , ELISA, 
ELISPOT, tetramer analysis and diverse in vitro cytotoxicity assays have provided us with 
valuable insights in relevant immunological mechanisms contributing to the proof of the 
principle and to our understanding of the complex interaction of the immune system and 
cancer cells. Regardless the assay used, there seem to be a fairly constant rate of about 50% 
immune responders in vaccinated cancer patients with malignant gliomas. Apart from a 
rare exception, most assays failed to correlate with clinical results. We should realize that we 
have to leave the former linear paradigm stating that cancer vaccines induce a detectable 
immune response that results in a detectable clinical response (tumor rejection), finally 
leading to improved overall survival. It did teach us however the important lesson that to 
date, dendritic cells indeed seem to be the best adjuvants available for clinical use to elicit 
measurable immune responses in cancer patients, even if almost all of them had been 
heavily pretreated with radio-and chemotherapy. It has to be mentioned that a rational 
combination of preferentially, non-myelo-ablative chemotherapy leading to ‘pro-
inflammatory’ immunogenic apoptosis of cancer cells rather synergizes than antagonizes 
with modern vaccine approaches. Several excellent reviews are dealing with that particular 
finding(20-22). 
Indeed, since recent years a growing consensus on the way to proceed with clinical 
research in cancer vaccine strategies has arisen. The Cancer Vaccine Clinical Trial 
Working Group already suggested  two parallel tracts of investigation: trials focusing on 
proof of principle and efficacy trials(23). The former should aim to demonstrate 
immunological activity, the latter should be designed to show clinical benefit for the 
patients. 
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The clinical outcome measures that really do have an impact on the patients’ perspectives 
are overall survival and quality of life. The well tolerated vaccinations often result in a 
minimal interference with a good quality of life, that is actually only being threatened by 
disease progression but not substantially by the therapy itself(24). The ambulatory nature 
of the vaccination schedules further contribute to this low impact on the treatment burden 
for the individual patient. Especially this low toxicity profile adds to the merits of this 
therapy in the subgroup of long-term surviving brain cancer patients. Indeed, even more 
than the possible statistically important impact on median survival data, the substantial 
group of patients with malignant glioma, both WHO grade III and IV lesions, surviving 
for many years after vaccination, is the best advocate of this therapeutic approach. Both 
newly diagnosed, but even more strikingly, relapsed and multi-relapsed patients with 
high grade gliomas display survival periods of more than 4 to 9 years (manuscript 
submitted). Considering the classical definition of long-term survivor in the malignant 
glioma literature, being patients surviving 24 or more months after diagnosis (of primary 
disease or relapse), substantial numbers of patients, including up to 25% of the relapsed 
HGG patients undergoing DC vaccination are actually benefitting this opportunity. These 
long-term survivors are not only an encouragement for this –even not fully mature -  
immunotherapy approach, but also a source of scientificly important translational 
knowledge to learn more about the factors predicting this type of outcome after 
immunotherapy. Final scientific proof of efficacy can of course only be delivered by well-
designed, sound randomized controlled trials, several of which are currently running 
throughout the world. 
4. Lack of standards: Disadvantage or opportunity for further improvement? 
The ’dendritic cell therapy for cancer’-world today is still characterized by a large variety of 
similar but not identical approaches. Even the definition of dendritic cell can slightly vary 
according to their progenitors with different resulting markers on their surface. Although 
direct harvesting from the peripheral blood is possible, some DC are differentiated out of 
stem cells or cord blood, but for the vast majority of clinical grade DC today, monocytes are 
harvested out of the peripheral blood and differentiated into DC. Different culture protocols 
and conditions result in different phenotypes, but the minimal criteria should be respected 
before one can claim the cells to be dendritic cells for clinical use: they should display clear 
cytoplasmic veils, have a high expression of MHC class II molecules as well as co-
stimulatory molecules like CD86 and have lost their ‘monocyte’ markers like CD14. 
Growing consensus is being reached about the mature DC being the preferred state of the 
cells to re-inject into the patients, rather than immature cells being able to tolerize rather 
than immunize the patient. Several maturation cocktails are being used, none of them 
however have been proven to be superior to the other variants in clinical use, although some 
evidence exists for the critical involvement of TNF┙ in the cocktail(25). As the serum of 
cancer patients might contain identified and unidentified immune suppressive agents 
inhibiting a good DC differentiation in ex vivo cultures, some favor the use of serum free 
culture conditions.  
Dendritic cells should be loaded with relevant glioma-associated antigens. The sources of 
these antigens differ widely from well-defined, possibly acid-eluted peptides, proteins, 
whole tumor cell lysates and homogenates, total tumor RNA, vector constructs, apoptotic 
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and necrotic bodies. The same lack of data about which source of antigen leads to the most 
effective vaccine construct is blurring a uniformal approach today. However, many 
theoretical considerations, could rather support the use of whole tumor cell antigens rather 
than well-defined single peptides. The most important argument against the exclusive use 
of a single peptide is the well-established phenomenon of selecting antigen-loss variants of 
the tumor, leading to an inevitable tumor escape of probably less immune susceptible tumor 
clones after vaccination. Moreover, the broad repertoire of whole tumor cell derived tumor 
associated antigens, will lead to presentation of the relevant processed antigens in any type 
of HLA constitution of the patient, both in an MCH class I and II context. An efficient 
immunization in these cases is more prone to result in a comprehensive polyclonal T and B 
cell activation able to provide a better coverage of different tumor clones of the intrinsic 
heterogenous malignant glioma cells. Nevertheless, further improvements might be 
expected if a more immunogenic apoptosis pathway could be used to create the source of 
tumor antigens. Nanoparticles could maybe improve uptake and processing efficiency in the 
DC and justify further investigation. 
Even harder to estimate today, is the optimal use of the appropriate danger signals (PAMP’s 
or pathogen associated molecular patterns or DAMP’s being danger associated molecular 
patterns)  to further increase the potency of the vaccine preparation(26). Several candidates, 
most of them being Toll-like receptor agonists, could substantially potentiate the clinical 
impact of the dendritic cell-based vaccine. To date, only preliminary data exist to support 
the use of e.g. imiquimod , poly I:C or clinical grade LPS in the clinical applications of DC 
vaccines. Several others like ssRNA even have to start being explored for this application. It 
is evident that with so many parameters being undecided in terms of the most clinically 
potent DC-based vaccination approach, that a large spectrum of DC-based vaccines result, 
going from the crude ‘dirty’ vaccines to the highly elaborated, often genetically engineered 
cell constructs. 
The lack of standards is not only to be found in the vaccine production arm, but even in 
the target population of patients to treat with DC-based vaccines. Most immunotherapy 
trials, not only those in brain cancer patients,  have been performed in end-stage patients, 
often heavily pre-treated. Anergic states, either induced by myelo-ablative regimens or by 
the advanced state of the cancer itself, compromise the theoretical potential of tumor 
vaccines. Mounting evidence exists nowadays, that DC-based cancer vaccines should be 
applied to patients with a minimal residual disease status rather than in end-stage cancer 
patients. Some researchers even advocate the use of cancer vaccines in pre-cancerous 
lesions, as such referring to the historical prophylactic nature of vaccines and the 
abundant evidence of the prophylactic efficacy of tumor vaccines in rodent models. In 
terms of glioma patients, this would imply a shift of the focus to patients with low grade 
gliomas, as these tumors tend to dedifferentiate over time to secondary high grade 
gliomas. It would however be very hard, if possible at all in this state of knowledge, to 
show any survival benefit of this approach in low grade gliomas as the natural course of 
this condition is so variable that one would need very extensive patient numbers to reach 
an adequate statistical power in any trial design. Malignant gliomas on the other hand, 
have the disputable statistical advantage of being rapidly progressive lesions with an 
almost invariable fatal outcome: a substantial deviation from this natural evolution in 
vaccinated patients will rapidly result in a broad clinical awareness and possible 
recognition of the value of cancer vaccines in this setting. 
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Not only the state of the disease, but also the patient’s age and possible timing of 
vaccination in the course of the treatment are relevant items to consider in the global 
treatment paradigm using DC-based vaccinations. Indeed, like in many types of oncological 
treatments, younger age seems to be correlated to a better response and survival after tumor 
vaccination. This can easily be understood as basic immunological features like thymic 
involution over time are very likely  to influence the potential of active specific 
immunotherapy approaches in general. As for timing of the implementation of 
immunotherapy, the question remains whether an upfront integration of the DC-based 
vaccines in the standard postoperative radiochemotherapy regimen(27) will result in a netto 
benefit over the alternative approach to apply DC-based tumor vaccination after re-
operation for recurrent disease as a single postoperative adjuvant treatment modality 
without interference of e.g. chemotherapy. Even more basic questions like the best 
frequency, dose, administration route and boost vaccine frequency and content are 
unanswered as yet. We do know that in DC-based tumor vaccination, no dose-response, nor 
dose-toxicity phenomenon is involved, but the optimal ‘pharmacological’ vaccine 
characteristics can only be concluded after further comparative clinical data.  
Although clinical trials with the current standards of tumor vaccines are mandatory to 
define the presumed position of cancer immunotherapy in the global oncological treatment 
regimens, we should realize ourselves that further improvements of the products itself will 
continue to be made in the next decade. This is of utmost importance to estimate the future 
potentials of the therapy without losing credits for further innovations of the technology 
itself. 
5. How to learn more? A difficult interplay between the technique, the tumor 
and the patient 
Three main areas of elucidation arise  at the moment. First of all,  intrinsic improvements 
of the vaccine details itself are to be monitored by advanced immune monitoring 
techniques(28). Apart from the classical monitoring assays aimed at detecting a specific 
anti-tumoral immune response, we should move towards a more global appreciation of 
the immune system and changes under therapy, both conventional and vaccination 
therapy. Indeed, preliminary evidence is emerging about the importance of the global 
immune status of the patient at time of diagnosis and treatment steps. 
Radiochemotherapy leads to a ‘re-setting’ of the patient’s immune system, possibly 
already then priming it towards a favorable or unfavorable starting position for 
subsequent immunotherapy. The vaccine itself might cause  quantitative and qualitative 
shifts in immune cell subtypes, not only regulatory or effector T cells, but also natural 
killer cells or natural killer T cells. We should start to include monitoring of local immune 
cells in the target environment, i.e. the brain and brain tumor micro-environment, rather 
than only in the blood, which is often not (at all) correlating with the local immune 
conditions in the target organs. Probably coinciding with shifts in cellular compartments 
of the immune system, cytokine environments might mimic the underlying changes and 
are good candidates to represent relevant switches in micro-environment facilitating or 
suppressing an effective tumor rejection by the immune system. Usually, a Th-1 pro-
inflammatory environment is believed to be beneficial for tumor rejection, although other 
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types of cytokine profiles, like e.g. a Th-17 mediated immune response are gaining 
importance in the global picture. Moreover, a TLR-agonist matured, fully Th-1 polarized 
DC vaccine has not yet been applied in larger clinical trials. A pro-inflammatory 
environment however is only facilitating a tumor rejection, if there’s no evolution to a 
chronic inflammatory state, like in chronic inflammatory diseases : in this particular 
situation indeed, the immune system exhibits important signs of immune exhaustion. 
Even this state can be detected and monitored to date in an increasingly accurate way e.g. 
by analyzing zeta-chain down regulation in the T cell compartments(29). Many other 
relevant cell types from tumor infiltrating macrophages (especially those with pro-tumor 
‘M2’ phenotype – called ‘alternatively activated macrophages’), or tumor infiltrating 
myeloid-derived suppressor cells (MDSC), both abundantly present in several glioma 
models and human glioma specimens are only beginning to be unraveled. Analogue to 
the regulatory T cell compartment, which has been recognized for years as a relevant 
player in the balance between tumor rejection and immune tolerance, the first preliminary 
reports arise about ‘regulatory dendritic cells’. It goes without saying that the fast 
acquisition of growing knowledge on the complex interplay between all these immune 
cells will influence our future understanding and concept of the current vaccine 
approaches. 
A second important source of contributing insights will come from the molecular analysis of 
the tumor specimens. The molecular profile of a malignant glioma with the characterization 
of MGMT promotor methylation status, 1p19q co-deletion, PTEN loss, IDH1 mutation etc is 
rapidly gaining access to the routine clinical assessment of a common high grade glioma. To 
the same extent, predictive (or prognostic) markers for immunotherapy will become 
available as there are already now the reports on tumoral HOX genes relevant for ‘immune 
reactions’ (30)or the suggestion of an ‘immunotherapy prone’ mesenchymal phenotype of 
the glioblastoma tumor cells(31). 
A third emerging field is the ‘predictive’ radiology field. In era’s of pseudo-progression and 
therapy-induced radiological changes on gadolinium(Gd)-enhanced MRI of the brain tumor 
patients, distinctive radiological techniques predicting a tumor response or a tumor 
progression are of utmost importance. Especially its non-invasive character turns MRI into a 
preferred monitoring tool for malignant glioma follow-up especially for the new therapy 
classes. Preliminary steps are being made to try to distinguish vaccine-induced radiological 
changes from tumor progression in Gd-enhancing lesions on the MRI, using perfusion-
weighted (regional cerebral blood volume-rCBV) and diffusion-weighted (apparent 
diffusion coefficient-ADC) images in combination with spectroscopic findings(18). In terms 
of correct patient counseling, these new monitoring paradigms are considered crucial for the 
near future. 
6. How to proceed? 
It is clear that we’re at a crucial step in the decision to move on with immunotherapy or not. 
Therefore we should acknowledge the particular difficulty to find a balance between 
gaining the appropriate clinical evidence that immunotherapy adds to the favorable 
outcome of the patients with high grade gliomas on the one hand and creating a stimulating 
environment for further optimalisation of an as yet immature technology on the other hand. 
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A too quick global ‘dissemination’ of today’s technologies will probably kill the credits for 
further development as too many aspects of the tumor vaccine approach itself are rapidly 
evolving towards a theoretical optimum.  
The combination of both objectives can be accomplished by performing further preclinical 
experiments and small-scale  early-clinical trials to optimize the vaccine technology as such 
and a gradual implementation of solid techniques of DC-based vaccine production and 
administration in large, randomized trials with the appropriate control arms to stepwise 
introduce the best available DC vaccine at that moment. The latter element is imperfect in se, 
but nevertheless highly required, even already at the moment, given the unmet medical 
need and the promising results for important subgroups of patients thus far. 
It is hard to predict the outline of the final, optimal DC-based vaccine for the future. 
Nevertheless it is clear it will have to integrate all the aspects of the difficult interplay 
between the technique, the tumor and the patient. Indeed, all of these three elements are 
highly relevant for a successful immunotherapy approach and probably for any approach at 
all. As for the anti-glioma DC-based vaccine production itself, preliminary evidence is being 
reported that whole tumor cell –based preparations are superior to defined epitopes in 
terms of overall survival data. Which types of other therapies that might synergize the most 
with cancer vaccines is subject of further investigations. Many candidates from radio-and 
chemotherapy over anti-angiogenesis, blood-brain barrier disruption techniques or 
oncolytic virus therapy do exist or are emerging today. Immune modulators and strategies 
able to modify the tumor micro-environment will play a crucial role in the future cancer 
vaccines. For anti-glioma vaccines, again many candidates immune modulators are at the 
edge of a clinical application to improve the overall vaccine efficiency. Substances like 
galectin-1, transforming growth factor ┚, interleukin 10, interleukin 6 and vascular 
endothelial growth factor are known to hamper vaccine efficiency and  might even be 
interconnected, so interference with either of these locally secreted factors could result in a 
dramaticly increased vaccine efficacy. Finally, the patient itself creates the background that 
might alter the impact of  all the interventions according to pre-existing parameters. In that 
regard, the notion of inherent immune cycles is an intriguing finding that needs however 
further clarification. Nevertheless, it might explain the indirect evidence we have for the 
tremendous importance of the timing of immunotherapy interventions on the final outcome 
of the patient. 
All this implies that we should consequently move into the direction of ‘individualized’ or 
‘customized’ cancer vaccines rather than mass-produced ‘off the shelf’ constructs. Therefore 
, we should not mix up the ideal medical tracts with the desired ‘manufacturing profile’ of a 
cancer vaccine. It is highly likely that clinical results in this area of research will proceed the 
elucidation of all the underlying mechanisms rather than vice versa. Also for regulating 
agencies  of cellular therapies, all the above mentioned aspects hold an enormous challenge 
but also a ‘life-important’ responsibility. 
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